AntibioticDB

Highest development stage: Phase 1

Development status: Unknown

Gram-negative activity

Mechanism of Action/Target pathogen: C. difficile infections

Reason dropped: Evotec and Bioveris collaborated to take this into phase II trials but there has been nothing to suggest it was taken into phase II. It was in phase I trials for nosocomial infections and CAP (source)

Additional information: Gray CP, Cappi MW, Frimodt-Moller N. Efficacy studies of MCB 3837, a dual-action antibiotic, in experimental infections in mice. 45th-Intersci-Conf-Antimicrob-Agents-Chemother 2005;185

GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10997

Source: https://www.businesswire.com/news/home/20180412006425/en/DEINOVE-Takes-New-Dimension-Acquisition-MORPHOCHEM%E2%80%99s-Clinical-Stage

Citation (1): https://www.globenewswire.com/news-release/2019/05/16/1826433/0/en/DEINOVE-is-now-ready-to-start-Phase-II-clinical-trial-for-its-antibiotic-compound-DNV3837.html

Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/44201349

Oxaquin (prodrug of MCB3681), DNV3837, MCB3837

Fluoroquinolone-oxazolidinone hybrid

Morphochem AG (Biovertis, Vienna); Evotec AG, Germany

2005